Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantargia ABCHIX:CANTAS 33 EV-to-OCF is 2.84 as of Aug. 12, 2026, which is 25% below its 10-year median of 3.80. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Cantargia AB ranks worse than 79.59% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cantargia AB's Enterprise Value is kr449.4 Mil.
Cantargia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr158.1 Mil. Therefore, Cantargia AB's EV-to-OCF for today is 2.84.
The historical rank and industry rank for Cantargia AB's EV-to-OCF or its related term are showing as below:
CHIX:CANTAs'
s EV-to-OCF Range Over the Past 10 Years
Min: 1.23 Med: 3.8 Max: 8.39
Current: 2.89
During the past 13 years, the highest EV-to-OCF of Cantargia AB was 8.39. The lowest was 1.23. And the median was 3.80.
CHIX:CANTAs's EV-to-OCF is ranked worse than 79.59% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs CHIX:CANTAs: 2.89
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cantargia AB's PE Ratio (TTM) for today is calculated as:
Cantargia AB's share price for today is kr4.174.
Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cantargia AB EV-to-OCF Related Terms
Cantargia AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cantargia AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Cantargia AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cantargia AB's EV-to-OCF falls into.
Cantargia AB's current Enterprise Value is kr449.4 Mil.
Cantargia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr158.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a EV-to-OCF of 2.84 as of Aug. 12, 2026. This is 25% below median its historical median of 3.80. Over the past decade, Cantargia AB's EV-to-OCF has ranged from 1.23 to 8.39. According to the industry distribution chart, Cantargia AB ranks #1119 out of 1406 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Cantargia AB's EV-to-OCF too high?
Cantargia AB's current EV-to-OCF of 2.84 is 25% below median its 10-year median of 3.80. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 8.39. Based on the distribution chart, Cantargia AB ranks #1119 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #1119 out of 1406 companies for EV-to-OCF. This places Cantargia AB in the lower half of its industry. Historically, Cantargia AB's own EV-to-OCF has ranged from 1.23 to 8.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cantargia AB's current EV-to-OCF is 2.84, which is 25% below median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current EV-to-OCF of 2.84. The current EV-to-OCF is 2.84, which is 25% below median its 10-year median of 3.80. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current EV-to-OCF is 2.84 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score
Get the complete analysis for CHIX:CANTAS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
